Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection
- PMID: 20446848
- PMCID: PMC2872049
- DOI: 10.1086/652749
Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection
Abstract
Background: Human immunodeficiency virus (HIV) replication and immune activation may increase inflammation and coagulation biomarkers. Limited data exist comparing such biomarkers in persons with and without HIV infection.
Methods: For persons 45-76 years of age, levels of high-sensitivity C-reactive protein (hsCRP), interleukin (IL)-6, D-dimer, and cystatin C were compared in 494 HIV-infected individuals in the Strategies for Management of Anti-Retroviral Therapy (SMART) study and 5386 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) study. For persons 33-44 years of age, hsCRP and IL-6 levels were compared in 287 participants in the SMART study and 3231 participants in the Coronary Artery Development in Young Adults (CARDIA) study.
Results: hsCRP and IL-6 levels were 55% (P < . 001) and 62 (P < . 001) higher among HIV-infected participants than among CARDIA study participants. Compared with levels noted in MESA study participants, hsCRP, IL-6, D-dimer, and cystatin C levels were 50%, 152%, 94%, and 27% higher, respectively (P < . 001, for each), among HIV-infected participants. HIV-infected participants receiving antiretroviral therapy who had HIV RNA levels 400 copies/mL had levels higher (by 21% to 60%) (P < . 001) than those in the general population, for all biomarkers.
Conclusions: hsCRP, IL-6, D-dimer, and cystatin C levels are elevated in persons with HIV infection and remain so even after HIV RNA levels are suppressed with antiretroviral therapy. Additional research is needed on the pathophysiology of HIV-induced activation of inflammatory and coagulation pathways, to guide potential interventions.
Conflict of interest statement
Russell Tracy reports being a paid Consultant to Abbott and Merck. No other authors have a commercial or other association that might pose a conflict of interest.
Figures
Comment in
-
Inflammation and complications of HIV disease.J Infect Dis. 2010 Jun 15;201(12):1783-5. doi: 10.1086/652751. J Infect Dis. 2010. PMID: 20446849 No abstract available.
Similar articles
-
Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease.AIDS. 2014 Jul 31;28(12):1791-6. doi: 10.1097/QAD.0000000000000344. AIDS. 2014. PMID: 25003720 Free PMC article.
-
Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection.J Infect Dis. 2014 Nov 1;210(9):1396-406. doi: 10.1093/infdis/jiu275. Epub 2014 May 9. J Infect Dis. 2014. PMID: 24813472 Free PMC article.
-
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.PLoS Med. 2008 Oct 21;5(10):e203. doi: 10.1371/journal.pmed.0050203. PLoS Med. 2008. PMID: 18942885 Free PMC article.
-
Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients.Curr Opin HIV AIDS. 2014 Jan;9(1):80-6. doi: 10.1097/COH.0000000000000019. Curr Opin HIV AIDS. 2014. PMID: 24275673 Free PMC article. Review.
-
Cardiovascular Complications of HIV-Associated Immune Dysfunction.Cardiol Res Pract. 2015;2015:302638. doi: 10.1155/2015/302638. Epub 2015 Jan 11. Cardiol Res Pract. 2015. PMID: 25648075 Free PMC article. Review.
Cited by
-
The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation.AIDS. 2015 Feb 20;29(4):463-71. doi: 10.1097/QAD.0000000000000545. AIDS. 2015. PMID: 25630041 Free PMC article.
-
IL-8 Alterations in HIV-1 Infected Children With Disease Progression.Medicine (Baltimore). 2016 May;95(21):e3734. doi: 10.1097/MD.0000000000003734. Medicine (Baltimore). 2016. PMID: 27227934 Free PMC article.
-
Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection.J Infect Dis. 2016 Aug 1;214(3):408-16. doi: 10.1093/infdis/jiw173. Epub 2016 Apr 30. J Infect Dis. 2016. PMID: 27132283 Free PMC article.
-
Social Genomics of Methamphetamine Use, HIV Viral Load, and Social Adversity.Ann Behav Med. 2022 Aug 30;56(9):900-908. doi: 10.1093/abm/kaab096. Ann Behav Med. 2022. PMID: 36039526 Free PMC article.
-
A role for TLR signaling during B cell activation in antiretroviral-treated HIV individuals.AIDS Res Hum Retroviruses. 2013 Oct;29(10):1353-60. doi: 10.1089/AID.2013.0115. Epub 2013 Aug 16. AIDS Res Hum Retroviruses. 2013. PMID: 23763346 Free PMC article.
References
-
- The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count – guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–22296. - PubMed
-
- Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol. 2002;156:871–881. - PubMed
-
- Cutter GR, Burke GL, Dyer AR, Friedman GD, Hilner JE, et al. Cardiovascular Risk Factors in Young Adults. The CARDIA Baseline Monograph. Cont Clin Trials. 1991;12(Supplement):1S–78S. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01AI46362/AI/NIAID NIH HHS/United States
- N01 HC048050/HC/NHLBI NIH HHS/United States
- U01 AI046362-01/AI/NIAID NIH HHS/United States
- N01HC95169/HL/NHLBI NIH HHS/United States
- N01 HC095161/HC/NHLBI NIH HHS/United States
- N01 HC095164/HC/NHLBI NIH HHS/United States
- N01-HC-95159/HC/NHLBI NIH HHS/United States
- R01 DK078510/DK/NIDDK NIH HHS/United States
- N01 HC048049/HC/NHLBI NIH HHS/United States
- N01HC95095/HL/NHLBI NIH HHS/United States
- N01 HC095169/HC/NHLBI NIH HHS/United States
- N01 HC095165/HC/NHLBI NIH HHS/United States
- N01HC48050/HL/NHLBI NIH HHS/United States
- U01 AI042170/AI/NIAID NIH HHS/United States
- N01 HC095163/HC/NHLBI NIH HHS/United States
- N01-HC-48048/HC/NHLBI NIH HHS/United States
- N01 HC095162/HC/NHLBI NIH HHS/United States
- U01 AI042170-12/AI/NIAID NIH HHS/United States
- U01AI042170/AI/NIAID NIH HHS/United States
- N01 HC048047/HC/NHLBI NIH HHS/United States
- N01 HC095167/HC/NHLBI NIH HHS/United States
- N01 HC048048/HC/NHLBI NIH HHS/United States
- N01-HC-48047/HC/NHLBI NIH HHS/United States
- N01HC48049/HL/NHLBI NIH HHS/United States
- N01 HC095166/HC/NHLBI NIH HHS/United States
- N01-HC-95095/HC/NHLBI NIH HHS/United States
- N01 HC095160/HC/NHLBI NIH HHS/United States
- N01-HC-48050/HC/NHLBI NIH HHS/United States
- N01 HC095095/HC/NHLBI NIH HHS/United States
- U01 AI046362/AI/NIAID NIH HHS/United States
- N01-HC-95169/HC/NHLBI NIH HHS/United States
- MC_U122886352/MRC_/Medical Research Council/United Kingdom
- N01HC95159/HL/NHLBI NIH HHS/United States
- N01-HC-48049/HC/NHLBI NIH HHS/United States
- N01HC48047/HL/NHLBI NIH HHS/United States
- N01 HC095168/HC/NHLBI NIH HHS/United States
- N01 HC095159/HC/NHLBI NIH HHS/United States
- N01HC48048/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials